Bone metabolism disorders and avascular bone necrosis: A further problem in HIV-infected patients?

Medicina Clinica

Volumn 119, Issue 3, 2002, Pages 103-108

  Gutiérrez Rodero, Félix ^a   Padilla Urrea, Sergio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; INDINAVIR; MEGESTROL ACETATE; NELFINAVIR; RALOXIFENE;

AVASCULAR NECROSIS; BONE DEMINERALIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; METABOLIC BONE DISEASE; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BONE DENSITY; BONE NECROSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; HUMANS; INCIDENCE; MALE; OSTEONECROSIS; OSTEOPOROSIS; PREVALENCE;

EID: 0037157731     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73331-9     Document Type: Review

References (55)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. DHHS Panel on clinical practices for the treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
4. Visceral abdominal-fat accumulation associated with use of indinavir
5. Symptomatic osteoporosis in two young HIV-positive African women
6. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy
7. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors
8. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus
9. Avascular necrosis of bone in patients with human immunodeficiency virus infection: Report of 6 cases and review of the literature
10. Osteonecrosis and human immunodeficiency virus infection
11. Avascular necrosis in HIV infection
12. Increasing incidence of avascular necrosis of the hip in HIV-infected patients
13. Osteonecrosis in HIV: A case-control study
14. Aseptic necrosis in HIV seropositive patients: A possible role for megestrol acetate
15. Osteonecrosis of the femoral head in HIV-1 patients: Four additional cases
16. Avascular necrosis in HIV+ patients: A possible link to protease inhibitors
17. Accelerated bone mineral loss in HIV-infected patients receiving antiretroviral therapy
18. Osteopenia in a randomized, multicenter study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia: Extended follow-up to 48 weeks
19. Osteoporosis
20. Osteoporosis, prevention, diagnosis and therapy
21. Alterations in bone turnover in HIV-positive patients
22. Bone mineral density in patients with human immunodeficiency virus infection
23. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study
24. Increased abdominal fat is associated with reduced bone density in HIV-infected men with lipoystrophy
25. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral-therapy-naive patients
26. Lack of association between visceral adiposity and osteopenia in HIV-infected individuals
27. Does race influence bone mineral density in HIV-infected individuals receiving HAART?
28. Osteopenia in HIV-infected men: Association with lactic acidemia and lower weight pre-antiretroviral therapy
29. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir
30. Osteopenia in HIV-infected patients: Is it the disease or is it the treatment?
31. Bone mineral loss through increased turnover in HIV-infected children treated with highly active antiretroviral therapy
32. Factors related to osteopenia in HIV-infected patients
33. A prospective comparative trial of bone mineral density in HIV-infected patients
34. Osteopenia and osteoporosis in HIV-infected patients
35. Osteoporosis in HIV-infected patients treated with HAART is independent of protesae inhibitor use
36. Osteopenia: A consecuence of HIV not HAART?
37. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome
38. Serum and urine markers of bone mineral metabolism in HIV infected patients taking protease inhibitor containing potent antiretroviral therapy
39. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
40. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function
41. Select HIV protease inhibitors alter bone and fat metabolism in vitro
42. Protease inhibitors inhibit in vitro conversion of 25 (OH)-vitamin D to 1,25 (OH) 2-vitamin D
43. Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis
44. Bone density at various sites for prediction of hip fractures
45. Bone fracture rates in HIV + patients receiving protease inhibitors vs. Non-PI regimens
46. Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus
47. Osteonecrosis: Current perspectives on pathogenesis and treatment
48. Low-dose corticosteroids and avascular necrosis of the hip and knee
49. Multiple site avascular necrosis in HIV infected patients
50. Avascular necrosis of bone in human immunodeficiency virus infection and antiphospholipid antibodies
51. Multiple site avascular necrosis: Beware of tuberculosis and human immunodeficiency virus-a rare but important cause
52. Avascular necrosis of the bone in HIV-infected patients: Incidence and associated factors
53. High prevalence of avascular necrosis (AVN) of the hip in HIV infection:Magnetic resonance imaging of 339 asymptomatic patients
54. Osteonecrosis in patients infected with HIV: A case-control study
55. The clinical spectrum of osteonecrosis in HIV infection. Patients characteristics, associated factors and outcome in a series of 23 cases